^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

CAR20.19.22 T

i
Other names: CAR20.19.22 T
Associations
Company:
Medical College of Wisconsin, Miltenyi Biotec
Drug class:
CD19-targeted CAR-T immunotherapy, CD20-targeted CAR-T immunotherapy, CD22-targeted CAR-T immunotherapy
Related drugs:
Associations
2ms
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=4, Terminated, Medical College of Wisconsin | All four patients had no in-vivo expansion and no meaningful response to therapy. At this point per FDA guidance we will not be treating more patients.
Enrollment change • Trial completion date • Trial termination • Trial primary completion date
|
BCL2 (B-cell CLL/lymphoma 2)
|
CAR20.19.22 T
1year
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=48, Active, not recruiting, Medical College of Wisconsin | Recruiting --> Active, not recruiting
Enrollment closed
|
BCL2 (B-cell CLL/lymphoma 2)
|
CAR20.19.22 T
over1year
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=48, Recruiting, Medical College of Wisconsin | N=36 --> 48
Enrollment change
|
BCL2 (B-cell CLL/lymphoma 2)
|
CAR20.19.22 T
over2years
CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies (clinicaltrials.gov)
P1, N=36, Recruiting, Medical College of Wisconsin | Not yet recruiting --> Recruiting
Enrollment open
|
BCL2 (B-cell CLL/lymphoma 2)
|
CAR20.19.22 T